Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today ...
Immunic (IMUX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Faisal Khurshid from Leerink Partners reiterated a Buy rating on the ...
February 10-11: BIO CEO & Investor Conference 2025. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in one-on-one meetings at this conference, taking place in New York.
As of 1:47:45 PM EST. Market Open. Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback